COMMUNIQUÉS West-GlobeNewswire

ANI Pharmaceuticals Announces Intent to Appeal Rulings in CG Oncology Matter
16/07/2026
Trial court denied Company’s motion for a new trial and judgment as a matter of law for unjust enrichment ANI intends to appeal rulings to the Delaware Supreme Court and continue to seek to recover the value of the [...]
Novartis Fabhalta® (iptacopan) receives FDA traditional approval as first and only complement inhibitor to significantly slow kidney function decline in primary IgAN
17/07/2026
Fabhalta slowed eGFR decline by 48% vs placebo over two years, demonstrating kidney function preservation 1 Clinically meaningful improvements of protein in urine observed as early as two weeks, with sustained reduction [...]
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
16/07/2026
BRISBANE, Calif., July 16, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammatory diseases that [...]
LifeStance to Host Second Quarter 2026 Earnings Conference Call on August 6, 2026
16/07/2026
SCOTTSDALE, Ariz., July 16, 2026 (GLOBE NEWSWIRE) -- LifeStance Health Group, Inc. (NASDAQ: LFST), one of the nation’s largest providers of outpatient mental healthcare, will issue its second quarter 2026 earnings [...]
DBV Technologies Reports Second Quarter and Half-Year 2026 Financial Results and Business Update
16/07/2026
Châtillon, France, July 16, 2026 DBV Technologies Reports Second Quarter and Half-Year 2026 Financial Results and Business Update Continued productive engagement with the FDA in support of the BLA for the VIASKIN® [...]
DBV Technologies Announces the Filing of its 2026 Half-Year Report ― Conditions for Accessing or Consulting the Report
16/07/2026
Châtillon, France, July 16, 2026 DBV Te c hnologies Announces the Filing of its 2026 Half-Year Report ― Conditions for Accessing or Consulting the Report DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq [...]
Favorable Medicare Coverage Decision Supports Commercial Adoption of iMDx GraftAssure Assay Portfolio
16/07/2026
Industry-wide coverage policy expands reimbursement framework for donor-derived cell-free DNA testing Supports iMDx's commercial strategy in transplant monitoring Final policy establishes recurring testing baseline [...]
Cosmos Health Share Buyback Surpasses $1 Million, Reaching 4.84 Million Shares; Continues Open Market Repurchases
16/07/2026
CHICAGO, July 16, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the “Company”) (NASDAQ:COSM) , a diversified, vertically integrated global healthcare group, today announced that it has repurchased an [...]
NativePath 2026: Launch Effective Native Path Creatine Supplements for Seniors To Support Muscle Building and Strength with L-Leucine in USA
16/07/2026
Announcing NativePath Creatine Supplement combines creatine monohydrate, L-leucine, and L-carnitine to support muscle strength, recovery, energy, and lean muscle growth for an active lifestyle and daily wellness routine [...]
Trethera and UCLA Publish Comprehensive Review Highlighting Deoxycytidine Kinase as a Novel Metabolic Target for Cancer Therapy
16/07/2026
Peer-reviewed publication positions TRE-515 as the first clinically tested dCK inhibitor and outlines a new therapeutic framework for targeting nucleotide metabolism in tumors LOS ANGELES, July 16, 2026 (GLOBE NEWSWIRE [...]
EssilorLuxottica: Second-Quarter and First-Half 2026 Results Conference Call Invitation
16/07/2026
Second-Quarter and First-Half 2026 Results Conference Call Invitation Mr FRANCESCO MILLERI, Chairman and Chief Executive Officer, Mr PAUL DU SAILLANT, Deputy Chief Executive Officer, Mr STEFANO GRASSI, Chief Financial [...]
Society for Medical Decision Making Honors UMIT TIROL and Harvard Professor Uwe Siebert with 2026 Career Achievement Award
16/07/2026
OSLO, Norway, July 16, 2026 (GLOBE NEWSWIRE) -- The Society for Medical Decision Making (SMDM) presented its highest career honor, the 2026 Career Achievement Award , to Professor Uwe Siebert, MPH, MSc, ScD , of UMIT [...]
EssilorLuxottica: Second-Quarter and First-Half 2026 Results Conference Call Invitation
16/07/2026
Second-Quarter and First-Half 2026 Results Conference Call Invitation Mr FRANCESCO MILLERI, Chairman and Chief Executive Officer, Mr PAUL DU SAILLANT, Deputy Chief Executive Officer, Mr STEFANO GRASSI, Chief Financial [...]
La Croix-Rouge canadienne vient en aide aux communautés frappées par les inondations à Ottawa
16/07/2026
Les sommes amassées soutiendront le rétablissement des personnes touchées par les inondations. OTTAWA, Ontario, 16 juill. 2026 (GLOBE NEWSWIRE) -- La Croix-Rouge canadienne travaille étroitement avec la Ville d’Ottawa [...]
Canadian Red Cross supports communities impacted by Ottawa flooding
16/07/2026
Funds raised will help people affected by the floods with their recovery OTTAWA, Ontario, July 16, 2026 (GLOBE NEWSWIRE) -- The Canadian Red Cross is working closely with the City of Ottawa and community partners to [...]
Adlai Nortye Announces First Patient Dosed in Intermittent Weekly Dosing Arm of Global Phase 1 Trial of Pan-RAS(ON) Inhibitor AN9025
16/07/2026
First patient dosed in intermittent QW dosing arm with AN9025 Intermittent dosing offers a differentiated approach in the pan-RAS(ON) inhibitor space and may widen the therapeutic window based on preclinical data Both [...]
Remix Therapeutics to Present at AACR Drug Discovery and Development Conference
16/07/2026
Presentation to Highlight Phase 1 REM-422 ACC Data Demonstrating 43% Overall Response Rate and Durable Responses Exceeding One Year with Favorable Safety Results WATERTOWN, Mass., July 16, 2026 (GLOBE NEWSWIRE) -- Remix [...]
EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
16/07/2026
WATERTOWN, Mass., July 16, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients with serious retinal diseases, [...]
Rinascera Therapeutics Launches with Clinical-Stage Pipeline to Transform the Treatment of Genetic Skin Diseases
16/07/2026
- Initial financing led by Double Point Ventures with participation from Olive Tree Capital, Civilization Ventures and Toba Capital - - Supports advancement of RIN-001 for Gorlin Syndrome and RIN-002 for Dystrophic [...]

Pages